Franklin Resources Inc. decreased its holdings in Gilead Sciences (NASDAQ:GILD) by 5.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,851,178 shares of the biopharmaceutical company’s stock after selling 730,420 shares during the period. Franklin Resources Inc. owned 1.06% of Gilead Sciences worth $992,343,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in GILD. Keel Point LLC lifted its stake in Gilead Sciences by 0.4% in the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock worth $221,000 after purchasing an additional 12 shares during the last quarter. National Asset Management Inc. lifted its stake in Gilead Sciences by 0.7% in the second quarter. National Asset Management Inc. now owns 26,270 shares of the biopharmaceutical company’s stock worth $1,862,000 after purchasing an additional 174 shares during the last quarter. Linscomb & Williams Inc. lifted its stake in Gilead Sciences by 10.1% in the second quarter. Linscomb & Williams Inc. now owns 5,806 shares of the biopharmaceutical company’s stock worth $411,000 after purchasing an additional 531 shares during the last quarter. Heritage Wealth Advisors lifted its stake in Gilead Sciences by 2.5% in the fourth quarter. Heritage Wealth Advisors now owns 26,523 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 642 shares during the last quarter. Finally, Hanson & Doremus Investment Management lifted its stake in Gilead Sciences by 35.7% in the fourth quarter. Hanson & Doremus Investment Management now owns 2,461 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 648 shares during the last quarter. 78.35% of the stock is owned by hedge funds and other institutional investors.
Several brokerages have issued reports on GILD. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Credit Suisse Group set a $80.00 price objective on shares of Gilead Sciences and gave the stock a “hold” rating in a research note on Wednesday, January 3rd. Leerink Swann decreased their price objective on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating for the company in a research note on Wednesday, February 7th. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price objective for the company in a research note on Monday, February 19th. Finally, Barclays reissued an “overweight” rating and issued a $95.00 price objective (up previously from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $88.61.
Shares of GILD stock opened at $75.47 on Wednesday. The company has a market cap of $98,075.59, a P/E ratio of 8.82, a price-to-earnings-growth ratio of -1.73 and a beta of 1.18. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.67 and a current ratio of 2.74. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $89.54.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. Gilead Sciences’s revenue was down 18.7% compared to the same quarter last year. During the same period last year, the company posted $2.70 earnings per share. sell-side analysts anticipate that Gilead Sciences will post 6.21 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Investors of record on Friday, March 16th were issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 3.02%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend was Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.
In related news, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $83.51, for a total transaction of $2,087,750.00. Following the transaction, the executive vice president now directly owns 62,738 shares of the company’s stock, valued at $5,239,250.38. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Robin L. Washington sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total transaction of $401,550.00. Following the transaction, the chief financial officer now directly owns 23,749 shares in the company, valued at $1,907,282.19. The disclosure for this sale can be found here. Over the last three months, insiders have sold 308,600 shares of company stock worth $24,328,226. 1.16% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Franklin Resources Inc. Has $992.34 Million Position in Gilead Sciences (GILD)” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.thelincolnianonline.com/2018/04/18/franklin-resources-inc-has-992-34-million-position-in-gilead-sciences-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.